Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Coherus Bio (NQ: CHRS ) 1.020 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Coherus Bio < Previous 1 2 3 4 5 6 7 8 9 Next > Coherus BioSciences Announces New Employment Inducement Grants July 21, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors July 20, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Mark Cuban's Pharmacy Company Lands Deal With Top 10 US Retailer: Here Are The Details July 19, 2023 Since launching the Mark Cuban Cost Plus Drug Company in 2022, entrepreneur and NBA team owner Mark Cuban has been on a mission to lower the cost of medicines for consumers. Via Benzinga 10 Analysts Have This to Say About Coherus BioSciences July 14, 2023 Via Benzinga Health Care Company Coherus BioSciences Announces Merger With Surface Oncology June 16, 2023 Via Benzinga Analyst Expectations for Coherus BioSciences's Future June 15, 2023 Via Benzinga Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients June 06, 2023 Via Benzinga Why Is AbbVie Stock Trading Down Today? June 01, 2023 AbbVie Inc. (NYSE: ABBV) shares are trading lower Thursday after Coherus BioSciences Inc. Via Benzinga Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™ July 13, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Cramer Is Still Bullish On AI Company Up 155% YTD: 'I Remain A Buyer' July 11, 2023 On CNBC’s "Mad Money Lightning Round," Jim Cramer said he's surprised by the slow progress of Rambus Inc. (NASDAQ: RMBS). Via Benzinga Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S. July 03, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Looking Into Coherus BioSciences's Return On Capital Employed May 23, 2023 Via Benzinga Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability June 20, 2023 Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc. Via Benzinga Nasdaq Down 80 Points; US Consumer Sentiment Surges To 4-Month High In June June 16, 2023 U.S. stocks traded lower toward the end of trading, with Nasdaq Compsoite dropping around 80 points on Friday. The Dow traded down 0.24% to 34,324.18 while the NASDAQ fell 0.59% to 13,701.06. The S&P... Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session June 16, 2023 Via Benzinga Stocks Headed For Strong Weekly Wins June 16, 2023 Stocks are struggling for direction midday, but all three major indexes are on track for strong weekly gains. Via Talk Markets Crude Oil Rises; Adobe Posts Upbeat Results June 16, 2023 U.S. stocks traded slightly higher midway through trading, with Dow Jones gaining around 20 points on Friday. The Dow traded up 0.06% to 34,428.13 while the NASDAQ rose 0.05% to 13,789.23. The S&P 500,... Via Benzinga Why Squarespace Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 16, 2023 Gainers Oncorus, Inc. (NASDAQ: ONCR) shares surged 258% to $0.2781. Via Benzinga Coherus BioSciences, MicroVision, Millicom And Other Big Stocks Moving Lower On Friday June 16, 2023 U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording losses in today’s session. Coherus BioSciences, Inc. (NASDAQ: CHRS) tumbled 16.8%... Via Benzinga US Stocks Mixed; Dow Gains 50 Points June 16, 2023 U.S. stocks traded mixed this morning, with Dow Jones gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.16% to 34,464.01 while the NASDAQ fell 0.14% to... Via Benzinga This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy? June 16, 2023 Coherus' biosimilar to Humira could catapult the company to success. Via The Motley Fool Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M June 16, 2023 Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that Via Benzinga Coherus to Acquire Surface Oncology June 16, 2023 From Surface Oncology, Inc. Via GlobeNewswire AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry June 15, 2023 AbbVie Inc (NYSE: ABBV) has challenged Coherus BioSciences Inc (NASDAQ: CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a... Via Benzinga Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma June 05, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2 June 02, 2023 Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics. Via Talk Markets Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed' June 01, 2023 One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug... Via Benzinga Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients June 01, 2023 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023 June 01, 2023 List price of $995 per carton for two 40 mg/0.8 mL autoinjectors From Coherus BioSciences, Inc. Via GlobeNewswire Top 5 Health Care Stocks That Could Blast Off In May May 26, 2023 The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.